Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Tonix Pharmaceuticals Holding Corp. - Common Stock
(NQ:
TNXP
)
19.56
+0.03 (+0.15%)
Streaming Delayed Price
Updated: 2:11 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tonix Pharmaceuticals Holding Corp. - Common Stock
< Previous
1
2
3
4
Next >
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
December 04, 2025
From
BioMedWire
Via
GlobeNewswire
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances TNX-2900 for Prader-Willi Syndrome Into Phase 2 Trial
September 30, 2025
Via
Investor Brand Network
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
August 06, 2025
Via
Investor Brand Network
Topics
Government
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
August 06, 2025
EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Government
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present TNX-801 Mpox Vaccine Data at Vaccine Congress 2025
July 07, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Publishes Preclinical Data Supporting TNX-1700 as Immunotherapy Enhancer in Gastric Cancer
July 02, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Added to Russell 3000 and Russell 2000 Indexes
June 30, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Phase 3 Data on Fibromyalgia Drug at EULAR 2025
June 16, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Appoints Jim Hunter to Board of Directors
June 13, 2025
Via
Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at 2025 BIO International Convention
June 10, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at EULAR 2025 in Barcelona
June 05, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO Joins A.G.P. Healthcare Showcase Fireside Chat
May 22, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Doses First Patient in DoD-Backed OASIS Trial for Acute Stress Reaction
May 21, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Appoints Joseph Hand as General Counsel and EVP of Operations
May 14, 2025
Via
Investor Brand Network
TechMediaBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Prepares for Potential Fibromyalgia Drug Approval, Reports Q1 Results
May 13, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Preclinical Data for TNX-1700 at AACR 2025
April 29, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Showcases Single-Dose Mpox Vaccine Data at World Vaccine Congress
April 24, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Collaborates With Makana Therapeutics on Xenotransplantation Research
April 09, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Data on Fibromyalgia Drug at AAPM 2025
April 07, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO to Present at 2025 Jones Trading Healthcare Conference
April 02, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Launches TONIX ONE™ Digital Platform to Transform Migraine Care
April 01, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Non-Opioid Fibromyalgia Drug Toward FDA Decision
March 31, 2025
Via
Investor Brand Network
Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year
March 31, 2025
Via
ACCESS Newswire
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc.
March 29, 2025
Via
ACCESS Newswire
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at AAPM 2025 PainConnect Meeting
March 27, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Fibromyalgia Drug Without Advisory Committee Review
March 24, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Single-Dose Vaccine for Mpox
March 20, 2025
Via
Investor Brand Network
As Mpox Cases Spread Around the World, Tonix Pharmaceuticals’ Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread
March 20, 2025
Via
ACCESS Newswire
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q4, Full-Year 2024 Financial Results, Highlights Key Developments
March 19, 2025
Via
Investor Brand Network
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
March 14, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.